Effectiveness and risk factors for virological outcome of darunavir-based therapy for treatment-experienced HIV-infected patients-Reference-Cited by-同舟云学术

Effectiveness and risk factors for virological outcome of darunavir-based therapy for treatment-experienced HIV-infected patients

Published:2015-09-24 Issue:1 Volume:12 Page:
ISSN:1742-6405
Container-title:AIDS Research and Therapy
language:en
Short-container-title:AIDS Res Ther

Author:

Mata-Marín José Antonio,Huerta-García Gloria,Domínguez-Hermosillo Juan Carlos,Chavez-García Marcelino,Banda-Lara Marco Isaac,Nuñez-Rodríguez Nohemí,Cruz-Herrera Javier Enrique,Sandoval-Ramírez Jorge Luis,Martínez-Abarca Ivan,Villagómez-Ruíz Alfredo Francisco,Manjarrez-Tellez Bulmaro,Gaytán-Martínez Jesús

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Virology,Molecular Medicine

Link

http://link.springer.com/content/pdf/10.1186/s12981-015-0072-9

Reference15 articles.

1. Mocroft A, Ledergerber B, Viard JP, Staszewski S, Murphy M, Chiesi A, et al. Time to virological failure of 3 classes of antiretrovirals after initiation of highly active antiretroviral therapy: results from the EuroSIDA study group. J Infect Dis. 2004;190:1947.

2. Katlama C, Esposito R, Gatell JM, Goffard JC, Grinsztejn B, Pozniak A, et al. Efficacy and safety of TMC114/ritonavir in treatment-experienced HIV patients: 24-week results of POWER 1. AIDS. 2007;21:395.

3. Renaud-Thery F, Nguimfack BD, Vitoria M, Lee E, Graaff P, Samb B, et al. Use of antiretroviral therapy in resource-limited countries in 2006: distribution and uptake of first- and second-line regimens. AIDS. 2007;21(Suppl. 4):S89.

4. Wilson LE, Gallant JE. The management of treatment-experienced HIV-infected patients: new drugs and drug combinations. Clin Infect Dis. 2009;48:214.

5. Clotet B, Bellos N, Molina JM, Cooper D, Goffard JC, Lazzarin A, et al. Efficacy and safety of darunavir–ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials. Lancet. 2007;369:1169.

Cited by 11 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prevalence of Drug Resistance and Genetic Transmission Networks Among Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome Patients with Antiretroviral Therapy Failure in Guangxi, China;AIDS Research and Human Retroviruses;2022-10-01

2. Real-World Characterization of the Portuguese Population Living with HIV who Initiated Raltegravir Based-Regimens: The REALITY Study;Acta Médica Portuguesa;2022-07-01

3. Clinical and demographic predictors of antiretroviral efficacy in HIV–HBV co-infected patients;Official Journal of the Association of Medical Microbiology and Infectious Disease Canada;2021-07

4. Long-term virological effectiveness with darunavir/ritonavir-based salvage therapy in people living with HIV/AIDS from São Paulo, Brazil;International Journal of STD & AIDS;2020-07-23

5. Zimbabwe’s national third-line antiretroviral therapy program: Cohort description and treatment outcomes;PLOS ONE;2020-03-02